转移性细胞癌的第一线免疫疗法:更新的网络元分析,包括三重疗法
Takafumi Yanagisawa1,2, Tatsushi Kawada1,3, Kensuke Bekku1,3
1Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
BJU international
|April 25, 2024
概括
布罗利祖马布加上伦瓦提尼布在中等或低风险患者的转移性细胞癌 (mRCC) 一线治疗中表现出优异的疗效. 三重疗法没有显著的益处,应该保留给精选的病例.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验中的临床试验.
背景情况:
- 转移性细胞癌 (mRCC) 提出了重大治疗挑战,特别是在中低风险疾病患者中.
- 基于免疫检查点抑制剂 (ICI) 的联合疗法已成为对mRCC的有希望的治疗方式.
- 最近的研究已经研究了三重疗法的疗效,包括尼沃卢马布加上伊皮利穆马布加上卡博桑提尼布,需要进行比较分析.
研究的目的:
- 为了比较一线ICI基组合疗法在中等和低风险mRCC患者的差异性疗效.
- 评估三重疗法 (nivolumab + ipilimumab + cabozantinib) 与其他一线ICI治疗方案的有效性.
- 评估瘤结果,包括无进展生存率 (PFS) 和客观反应率 (ORR),以及与治疗相关的不良事件.
主要方法:
- 在2022年12月,针对随机对照试验 (RCT) 在三个数据库中进行了系统的文献搜索.
- 进行了网络元分析 (NMA),以比较中等和低风险mRCC患者的瘤结果和不良事件.
- 包括七个RCT,分析无进展生存期 (PFS),客观反应率 (ORRs) 和与治疗相关的不良事件.
主要成果:
- 在中低风险mRCC患者中, pembrolizumab加lenvatinib显示最有可能改善PFS (99%) 和ORRs (99.7%).
- 与尼沃卢马布+卡博桑提尼布相比,三重治疗 (尼沃卢马布+伊皮利穆马布+卡博桑提尼布) 并没有显示出优异的PFS.
- 潘布罗利祖马布和伦瓦提尼布的疗效在国际转移性RCC数据库联盟 (IMDC) 风险组中一致.
结论:
- 布罗利祖马布加上伦瓦提尼布是中等或较低IMDC风险的mRCC患者的强大的第一线治疗选择.
- 三疗法没有产生优异的疗效,并且由于毒性和不成熟的整体存活数据,只应考虑在选定的患者中使用.
- 需要进一步评估,以充分了解长期影响,并为三重疗法选择最佳患者.
关键词:
卡博桑提尼布 (cabozantinib) 是一种药物.免疫检查点抑制剂 免疫检查点抑制剂这里是 ipilimumab 的所在地.转移 转移 转移 转移这就是尼沃卢马布 (nivolumab).细胞癌瘤是细胞癌.更多相关视频
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
16.6K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
相关概念视频
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K